Literature DB >> 1078596

A community study of the relation of alpha1-antitrypsin levels to obstructive lung diseases.

J O Morse, M D Lebowitz, R J Knudson, B Burrows.   

Abstract

Since it is still uncertain whether moderate degrees of alpha1-antitrypsin deficiency predispose to the development of lung disease, data obtained from a stratified random sample of white households in Tucson, Arizona, consisting of 2586 subjects over five years of age, were analyzed. No relation was found between serum alpha1-antitrypsin levels, measured as trypsin inhibitory capacity, and ventilatory function, respiratory symptomatology, or frequency of diagnosed pulmonary diseases even among cigarette smokers. The data indicate that an intermediate level of alpha1-antitrypsin deficiency (i.e., inhibitory capacity between 20 and 62 per cent of the population's mean value) is not an important risk factor for the development of chronic obstructive lung diseases. The data militate strongly against the use of any quantitative determination of alpha1-antitrypsin as a test to identify subjects with moderate deficiency for the purpose of predicting later development of chronic respiratory disorders. The rate of severe deficiency is so low as to make population screening for such subjects impractical.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1078596     DOI: 10.1056/NEJM197502062920602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  11 in total

1.  Pulmonary abnormalities in intermediate alpha-1-antitrypsin deficiency.

Authors:  W J Hall; R W Hyde; R H Schwartz; G S Mudholkar; D R Webb; Y P Chaubey; P L Townes
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

2.  The periodic health examination. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

Review 3.  Utility of serologic testing in the diagnosis of noninfectious pulmonary disorders.

Authors:  R H White; J A Golden
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

4.  Alpha1-antitrypsin phenotypes and lung function in a moderately polluted northern Ontario community.

Authors:  D N Ostrow; J Manfreda; T Dorman; R M Cherniack
Journal:  Can Med Assoc J       Date:  1978-03-18       Impact factor: 8.262

5.  Cockayne's syndrome and emphysema.

Authors:  M Cunningham; S Godfrey; W M Moffat
Journal:  Arch Dis Child       Date:  1978-09       Impact factor: 3.791

6.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

Review 7.  Relation of alpha-1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population.

Authors:  R B Cole; N C Nevin; G Blundell; J D Merrett; J R McDonald; W P Johnston
Journal:  Thorax       Date:  1976-04       Impact factor: 9.139

8.  Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase.

Authors:  F Ogushi; G A Fells; R C Hubbard; S D Straus; R G Crystal
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

9.  Risk factors for emphysema. Cigarette smoking is associated with a reduction in the association rate constant of lung alpha 1-antitrypsin for neutrophil elastase.

Authors:  F Ogushi; R C Hubbard; C Vogelmeier; G A Fells; R G Crystal
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

10.  alpha 1-Antitrypsin deficiency and susceptibility to lung disease.

Authors:  H E Evans; N Bognacki
Journal:  Environ Health Perspect       Date:  1979-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.